Evidence map›Paper›PMID 24853424›Full record

ArticleCell death & disease2014

Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence.

I Ramachandran, V Ganapathy, E Gillies, I Fonseca, S M Sureban, C W Houchen, A Reis, L Queimado

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 88 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. TREX1 suppression imparts cancer-stem-cell-like characteristics to CD133International journal of clinical and experimental pathology · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

I RamachandranDepartment of Otorhinolaryngology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
V GanapathyDepartment of Otorhinolaryngology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
E GilliesDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
I FonsecaServiço de Anatomia Patológica, Instituto Português de Oncologia de Francisco Gentil and Instituto de Anatomia Patológica, Faculdade de Medicina de Lisboa, Lisbon, Portugal.
S M Sureban1] US Department of Veterans Affairs Medical Center, Oklahoma City, OK, USA [2] Peggy and Charles Stephenson Oklahoma Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA [3] Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
C W Houchen1] US Department of Veterans Affairs Medical Center, Oklahoma City, OK, USA [2] Peggy and Charles Stephenson Oklahoma Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA [3] Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
A ReisDepartment of Dermatology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
L Queimado1] Department of Otorhinolaryngology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA [2] US Department of Veterans Affairs Medical Center, Oklahoma City, OK, USA [3] Peggy and Charles Stephenson Oklahoma Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA [4] Department of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA [5] Department of Pediatrics, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA [6] The Oklahoma Tobacco Research Center, Oklahoma City, OK, USA.
University of Oklahoma Health Sciences Center · USUnited States Department of Veterans Affairs · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperactivation of the Wingless-type (Wnt)/β-catenin pathway promotes tumor initiation, tumor growth and metastasis in various tissues. Although there is evidence for the involvement of Wnt/β-catenin pathway activation in salivary gland tumors, the precise mechanisms are unknown. Here we report for the first time that downregulation of the Wnt inhibitory factor 1 (WIF1) is a widespread event in salivary gland carcinoma ex-pleomorphic adenoma (CaExPA). We also show that WIF1 downregulation occurs in the CaExPA precursor lesion pleomorphic adenoma (PA) and indicates a higher risk of progression from benign to malignant tumor. Our results demonstrate that diverse mechanisms including WIF1 promoter hypermethylation and loss of heterozygosity contribute to WIF1 downregulation in human salivary gland tumors. In accordance with a crucial role in suppressing salivary gland tumor progression, WIF1 re-expression in salivary gland tumor cells inhibited cell proliferation, induced more differentiated phenotype and promoted cellular senescence, possibly through upregulation of tumor-suppressor genes, such as p53 and p21. Most importantly, WIF1 significantly diminished the number of salivary gland cancer stem cells and the anchorage-independent cell growth. Consistent with this observation, WIF1 caused a reduction in the expression of pluripotency and stemness markers (OCT4 and c-MYC), as well as adult stem cell self-renewal and multi-lineage differentiation markers, such as WNT3A, TCF4, c-KIT and MYB. Furthermore, WIF1 significantly increased the expression of microRNAs pri-let-7a and pri-miR-200c, negative regulators of stemness and cancer progression. In addition, we show that WIF1 functions as a positive regulator of miR-200c, leading to downregulation of BMI1, ZEB1 and ZEB2, with a consequent increase in downstream targets such as E-cadherin. Our study emphasizes the prognostic and therapeutic potential of WIF1 in human salivary gland CaExPA. Moreover, our findings demonstrate a novel mechanism by which WIF1 regulates cancer stemness and senescence, which might have major implications in the field of cancer biology.

Indexed as

Cellular SenescenceWnt Signaling PathwayAdaptor Proteins, Signal TransducingAdenoma, PleomorphicBiomarkers, TumorCarcinomaCell Cycle CheckpointsCell Cycle ProteinsCell Line, TumorCell ProliferationDisease ProgressionDNA MethylationDown-RegulationGene Expression Regulation, NeoplasticHumansLoss of HeterozygosityAdaptor Proteins, Signal TransducingBiomarkers, TumorCell Cycle ProteinsMicroRNAsRepressor ProteinsWIF1 protein, human

Identifiers

PMID24853424
PMCPMC4047921
OpenAlexW2048182455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.